FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

11556411000001102: Tarceva 25mg tablets (Roche Products Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-Oct 2007. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
42353501000001113 Tarceva 25mg tablets (Roche Products Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
42353601000001112 Tarceva 25mg tablets (Roche Products Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Tarceva 25mg tablets (Roche Products Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Is a Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has active ingredient Erlotinib false Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has manufactured dose form Conventional release oral tablet true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has excipient Lactose false Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Is a Tarceva true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Erlotinib true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has specific active ingredient Erlotinib hydrochloride true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has active ingredient Erlotinib hydrochloride false Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) Has basis of strength substance Erlotinib true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Tarceva 25mg tablets (Roche Products Ltd) 30 tablet Is pack of False Tarceva 25mg tablets (Roche Products Ltd) Inferred relationship Existential restriction modifier
Tarceva 25mg tablets (Roche Products Ltd) 30 tablet Has AMP True Tarceva 25mg tablets (Roche Products Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start